Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis.

ABSTRACT:

Background

Treatment with cladribine tablets (CladT) in relapsing-remitting multiple sclerosis (RRMS) reduced global grey matter (GM) atrophy, but the effects on regional GM are unknown.

Objectives

This study aimed to investigate the effect of CladT compared with placebo on magnetic resonance imaging (MRI)-derived patterns of GM atrophy.

Methods

We used MRI and clinical data from the CLARITY study, including 393 people with RRMS (CladT (3.5 mg/kg), n = 200 or placebo, n = 193) at baseline, 24, 48 and 96 weeks after treatment initiation. SynthSeg-derived volume changes and GM atrophy patterns derived from source-based morphometry were analysed for group differences over time and associations with disability using mixed-effect models.

Results

Deep G

SUBMITTER: Barrantes-Cepas M 

PROVIDER: S-EPMC12092944 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature